What's Happening?
The National Institute for Health and Care Excellence (NICE) has initiated a new consultation on its draft guidance for Alzheimer’s treatments donanemab and lecanemab. This follows an appeal by the drugs' manufacturers after NICE previously rejected them
for NHS use, citing high costs. The consultation, which began on March 31, 2026, will close on April 28, 2026, with a committee meeting scheduled for June 10, 2026, to evaluate the evidence. The manufacturers argued that they were not given adequate time to respond to certain decision-making processes, including NHS cost estimates. NICE is now reconsidering the impact of these drugs on caregivers and the long-term data associated with their use.
Why It's Important?
This development is significant as it highlights the ongoing challenges in balancing drug efficacy, cost, and accessibility within public health systems. The outcome of this consultation could influence future NHS policies on drug approval and funding, potentially affecting thousands of Alzheimer's patients and their caregivers. The decision could also set a precedent for how similar cases are handled, impacting pharmaceutical companies' strategies in drug pricing and market access.
What's Next?
Stakeholders, including the manufacturers and healthcare professionals, are expected to provide feedback during the consultation period. The upcoming committee meeting will be crucial in determining whether these drugs will be approved for NHS use. The decision will likely influence future drug appraisals and the development of new treatments for Alzheimer's disease.
